Jeremy Adler, CCC 2022: The Simplified Endoscopic Mucosal Assessment of Crohn’s Disease (SEMA-CD)
We were delighted to speak with Professor Jeremy Adler (Michigan Medicine, University of Michigan, Ann Arbor, MI, USA) around his talk around the findings from the validation study of the Simplified Endoscopic Mucosal Assessment of Crohn’s Disease (SEMA-CD).
The abstract entitled ‘VALIDATION OF THE SIMPLIFIED ENDOSCOPIC MUCOSAL ASSESSMENT OF CROHN’S DISEASE (SEMA-CD) A NOVEL ENDPOINT TO ASSESS ENDOSCOPIC IMPROVEMENT WITH REAL WORLD DATA’ was presented at the virtual 2022 Crohn’s & Colitis Congress, 20-22 January, 2022.
- Why is there a need for an endoscopic mucosal assessment in clinical practice? (0:23)
- Could you tell us a little about the Simplified Endoscopic Mucosal Assessment of CD (SEMA-CD)? (1:24)
- What were the aims and design of your validation study? (2:08)
- What were the findings of the study? (2:48)
- What are the implications of these findings for clinical practice and future clinical trial design? (5:22)
Disclosures: Jeremy Adler discloses consulting for Janssen Research & Development, LLC; and receiving grant/ research support from Janssen Research & Development, LLC.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual Crohn’s & Colitis Congress 2022.
Share this Video
Related Videos In Digestive Disorders
QUASAR: phase 3 study of guselkumab in moderately to severely active ulcerative colitis: Jessica Allegretti, DDW 2023
The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]
Guselkumab: an investigational monoclonal antibody for ulcerative colitis: Jessica Allegretti, DDW 2023
Guselkumab is a fully human monoclonal antibody IL-23 p19 subunit antagonist currently being investigated in hard to treat, moderately to severely active ulcerative colitis. We were delighted to speak with Dr Jessica Allegretti, (Brigham and Women’s Hospital, Boston, MA, USA) around the burden of ulcerative colitis in patients with inadequate response to currently approved treatments, […]
UEG Digestive Health Month: Matthias Löhr, May 2023
Digestive Health Month took place over May 2023 to raise awareness of digestive diseases and cancers, which often remain overlooked in terms of policy, funding and research in Europe. We were delighted to talk with UEG’s Vice President Prof. Matthias Löhr (Karolinska Institutet, Stockholm, Sweden) around the public health and economic burden of digestive diseases, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!